Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE), Novartis AG (ADR) (NVS): Does Incyte Corporation (INCY) Deserve Its New Valuation?

So about this pop…
The reason shares shot higher by nearly one-third today has a lot to do with the big picture. Sure, the news revolved around Jakafi’s potential in pancreatic cancer, but it was also one of the first studies to show that treating the JAK pathway is a viable option for treating the disease. And it wasn’t really close for the placebo. Things are a bit different for treating autoimmune diseases, but the news still reminds investors that Incyte and its partners could be onto something big. Really big.

I’ve been eyeing shares of Incyte Corporation (NASDAQ:INCY) for a long time, but will now wait for a pullback — if it occurs — to begin a position. You could make a solid argument that the company is undervalued at just $5.5 billion, too. What are your thoughts? Let me know in the comments section below.

The article Does Incyte Deserve Its New Valuation? originally appeared on Fool.com and is written by Maxx Chatsko.

Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology.The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.